Clinical Trial Update: A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/Phase 2 study of the NLRP3 inhibitor VENT-02 for Parkinson disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• VENT-02

Snippet

Sponsor: Ventus Therapeutics U.S., Inc. | Conditions: Parkinson Disease | Phase 1, Phase 2 | Status: TERMINATED